Akero Therapeutics (AKRO)
(Real Time Quote from BATS)
$53.93 USD
-0.12 (-0.22%)
Updated Nov 6, 2025 11:34 AM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKRO 53.93 -0.12(-0.22%)
Will AKRO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.

Other News for AKRO
The technical outlook for AKRO is unchanged after it rises 0.04% on November 5
The technical outlook for AKRO is unchanged after it falls 0.11% on November 4
Technical picture remains unchanged for AKRO after it falls 0.2% on November 3
Madrigal Pharmaceuticals upgraded at BofA on Rezdiffra uptake
Sell Novo Nordisk And Buy Viking Therapeutics